J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business
You may also be interested in...
Pfizer To House Consumer, Nutritional Divisions In Diversified Businesses Unit
Pfizer will appoint Wyeth's consumer health president to manage its new Diversified Businesses group, which will include consumer, nutritional and animal health, as part of a reorganization following the companies' planned merger
Pfizer To House Consumer, Nutritional Divisions In Diversified Businesses Unit
Pfizer will appoint Wyeth's consumer health president to manage its new Diversified Businesses group, which will include consumer, nutritional and animal health, as part of a reorganization following the companies' planned merger
Pfizer To House Consumer, Nutritional Divisions In Diversified Businesses Unit
Pfizer will appoint Wyeth's consumer health president to manage its new Diversified Businesses group, which will include consumer, nutritional and animal health, as part of a reorganization following the companies' planned merger